Dexcom filed the G7 with the FDA by the end of So most likely, we will see that approved before too long in and Dexcom will conduct an initial limited launch before eventually rolling the G7 out more broadly across the United States later in the year.

Made by Senseonics and sold by Ascensia Diabetes Care, the Eversense implantable CGM is a first of its kind that has been available in the United States since The next-generation version under development would allow for the same tiny sensor to be implanted for days or 6 months rather than 3.

This version will also reduce the number of fingerstick calibrations needed down from two to just one per day, according to the company. We may very well see this appear in The company submitted the Tempo Smart Button to the FDA in , as did Welldoc with its new app.

Those are still under FDA review and pending k clearance. The expectation is the system will get approval and launch in Since hitting the U. market in , this system has allowed PWDs to get a glucose reading whenever they want just by scanning the little white round sensor worn on the arm.

The Libre 2 became available in , offering optional alerts for low and high blood sugars. The mobile app was released in , which eliminated the need to scan the sensor with the handheld reader.

But Libre 3 promises to elevate the tech to full-CGM functionality because it will no longer require any sensor scanning to provide real-time glucose readings. Instead, Libre 3 generates a real-time glucose reading every minute, displaying that result on the compatible mobile app on iPhone or Android.

This continuous stream of data allows optional alerts for high and low blood sugars, along with glucose results. This is a big leap forward compared to Libre 2 that still requires a confirmation scan to get a numeric reading.

Per Abbott, that is a more than 70 percent size reduction that uses 41 percent less plastic. Our experts continually monitor the health and wellness space, and we update our articles when new information becomes available.

Insulet's Omnipod 5 becomes the first commercially available Automated Insulin Delivery AID system with no tubes and smartphone control. The diaTribe Foundation has launched a new resource hub to help people with diabetes fight stigma. Are continuous glucose monitors and insulin pumps covered by Medicare?

Everything you need to know about what about birth control options and concerns for women with type 1 diabetes. Everything you need to know about preparing for travel and TSA rules with type 1 diabetes as COVID subsides. A diabetes advocate in Ireland explains the patient community and St.

Patrick's Day. Cauliflower Pizza is now big business. Why is this so exciting for people with type 1 diabetes? DiabetesMine interviews researcher Dr. Howard Wolpert on technology and other progress revolutionizing diabetes care.

The exciting first-ever implantable continuous glucose monitor CGM Eversense can now be worn for 6 months straight. A Quiz for Teens Are You a Workaholic? How Well Do You Sleep? Health Conditions Discover Plan Connect.

Diabetes Mine Influencer New Diabetes Technology: What to Expect in By Mike Hoskins on January 6, — Fact checked by Jennifer Chesak, MSJ. Tandem Diabetes Care. Share on Pinterest Image via Tandem Diabetes Care. Omnipod 5 tubeless system.

Share on Pinterest Image via Insulet Corp. Medtronic Diabetes technology. Dexcom G7. Infusion-Site Reactions: CSII is associated with increased risk of infusion-site reactions compared with MDI, including contact dermatitis and infections; these are the most common complications associated with pump therapy.

Use of sterile techniques may help prevent skin infections; this includes washing hands thoroughly with soap and water prior to inserting an infusion set; avoiding breathing on the infusion set or site and avoiding touching the face during this process; using an alcohol pad to cleanse the skin of bacteria before insertion; and changing the infusion set frequently at a minimum, every 72 hours.

Diabetic Ketoacidosis: It is thought that with the use of rapid-acting insulin only, the failure of the pump to deliver insulin to a patient with T1DM could lead to low levels of insulin in the body after only a few hours. This process results in ketone bodies, an acidic byproduct, which can lead to an acidic state called diabetic ketoacidosis DKA.

Despite this theory, research has not demonstrated an increased risk of DKA for CSII compared with MDI. Patients starting on CSII therapy should be educated on the importance of recognizing signs and symptoms of DKA, how to monitor for ketones using urine and blood ketone strips, and how to treat if DKA is suspected.

Fear of Feeling Dependent on a Pump: While on CSII therapy, patients are rarely without their insulin pump, in contrast to patients using MDI, who are able to inject their insulin and remove themselves from their medication.

Because of this, patients may feel apprehensive about being attached to or dependent on the insulin pump, especially children and adolescents. Retinopathy: In the DCCT, patients with moderate or advanced retinopathy experienced worsened symptoms with intensive insulin therapy compared with conventional therapy within the first year of CSII treatment.

This worsening of symptoms often disappeared within 18 months. Table 2 discusses many misconceptions about CSII therapy. It is important for patients to meet with a certified insulin-pump trainer or certified diabetes educator to discuss their concerns before starting on an insulin pump.

Table 3 lists the insulin pumps currently available in the U. by prescription. It has been FDA approved and is now available for patient use. Associated-Meter or Continuous Glucose Monitor: Most insulin pumps on the market are associated with a glucometer or continuous glucose monitor CGM.

Communication between the meter or CGM and the insulin pump allows the BG level to be sent directly to the insulin pump using Bluetooth or radio-frequency technology. This eliminates the need for the patient to input the measured BG into his or her bolus calculator.

This automation has many benefits, including speeding up the process of calculating a bolus dose, increasing accuracy, and decreasing risk of incorrect bolus doses given because of an incorrect BG entry.

The integration also allows for a more comprehensive history that can be combined into one database to improve the confidence of providers in recommending adjustments to basal rates, bolus doses, IC ratios, and ISFs to optimize patient outcomes.

It is currently recommended that CGMs be used in the management of patients with DM. The patient wears the CGM for 6 or 7 days before discarding it and replacing it with a new sensor. Some of the current insulin pumps are integrated with a CGM and can receive BG data from the sensor.

If the CGM is not connected to a pump, the sensor can wirelessly transmit BG to a handheld receiver. The FDA recently approved the use of the Dexcom G5 CGM to adjust insulin doses. Tubeless Pumps: Currently, the only wearable pump that does not require tubing to connect the pump to the infusion site is the Omnipod Insulet.

This pump adheres to the skin directly. The Omnipod uses a wireless personal data manager that works in conjunction with the pump to insert a flexible plastic cannula directly from the wearable device and administer boluses, and it serves as a glucometer.

Instead of the infusion set and tubing being replaced, as would be required with traditional insulin pumps, the entire Omnipod is removed and discarded every 2 to 3 days depending on insulin requirement.

Alarms and Reminders: Alarms and reminders vary among individual pumps. However, there are many types of reminders that a patient can use. These can include low battery, low cartridge selected number of units left in reservoir , delivery limit, reminder to test BG and change infusion site, high or low glucose alert, automatic sleep, alert for a missed meal, and alarms for other special features the pump may possess.

Prediction alerts utilizing BG trend data have the capability to warn of a predicted high or low BG in advance of reaching these thresholds.

Additional Pump Features: With upgrades in technology, many pumps have multicolor screens. Some pumps have touch screens, similar to smartphones. Bluetooth and other wireless-technology compatibility allows patients to download their pump, glucometer, or CGM data directly to smartphone applications or computers.

Pumps may have food libraries stored within them that provide information on carbohydrate content. Additional accessories, such as remote controls, are also available. Pharmacists can be involved in the care of patients receiving CSII therapy by becoming a certified diabetes educator or a certified pump trainer for one or more insulin-pump companies.

These certifications may require additional training and education, a specified number of hours of experience with DM patients, and successful completion of competency examinations. who have successfully implemented CSII initial training, management, and education of patients with DM.

These individuals have been able to receive reimbursement for their services. Many diabetic patients have opted to control their DM with CSII therapy, and the number of insulin-pump patients is expected to increase in the coming years.

However, it also poses some risks that should not be taken lightly. Patients considering CSII therapy should learn about the benefits and limitations of insulin pumps so that they can make an informed decision.

When deciding upon a specific pump, CSII candidates should research all available pumps, compare and contrast each one, and choose the pump that they feel will assist in improving their particular difficulties in managing DM successfully. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump.

N Engl J Med. Pickup JC, White MC, Keen H, et al. Long-term continuous subcutaneous insulin infusion in diabetics at home. Walsh J, Roberts R. Pumping Insulin: Everything You Need to Succeed on an Insulin Pump.

San Diego, CA: Torrey Pines; American Diabetes Association. Insulin pumps need greater safety review: American Diabetes Association issues joint statement with European Association for the Study of Diabetes.

March 16, Accessed November 30, Insulin infusion pumps panel information. General Hospital and Personal Use Medical Devices Panel. March The Diabetes Control and Complication Trial Research Group.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Steineck I, Cederholm J, Eliasson B, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18, people with type 1 diabetes: observational study.

American Association of Diabetes Educators Consensus Summit. Insulin pump therapy: guidelines for successful outcomes.

Chicago, IL: September 18, American Association of Diabetes Educators. Education for continuous subcutaneous insulin infusion pump users.

Diabetes Educ. Pickup JC, Sutton AJ. Severe hypoglycemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.

Diabet Med. Retnakaran R, Hochman J, DeVries JF, et al. Continuous subcutaneous insulin infusion versus multiple daily injections. The impact of baseline A1c. Diabetes Care. Little SA, Leelarathna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2x2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring HypoCOMPaSS.

Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion CSII therapy: an observational study of consecutive patients followed for a mean of 2 years.

Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study.

The Study Group for the Development of Pump Therapy in Diabetes. Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia.

J Pedtr Endocrinol Metab. Weintrob N, Schechter A, Benzaquen H, et al. Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion.

Arch Pediatr Adolesc Med. Hoogma RP, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion CSII and NPH-based multiple daily insulin injections MDI on glycaemic control and quality of life: results of the 5-nations trial.

Coloquitt JL, Green C, Sidhu MK, et al. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials.

Koivisto V, Yki-Jarvinen H, Helve E, et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Potti L, Haines S. Continuous subcutaneous insulin infusion therapy: a primer on insulin pumps. Pharmacy Today. Chantelau E, Schiffers T, Schutze J, Hansen B.

Effect of patient-selected intensive insulin therapy on quality of life. Patient Educ Couns. Hirsch IB, Bode BW, Garg S, et al. Scheidegger U, Allemann S, Scheidegger K, Diem P.

Continuous subcutaneous insulin infusion therapy: effects on quality of life. Swiss Med Wkly. Shapiro J, Wigg D, Charles MA, Perley M. Personality and family profiles of chronic insulin-dependent diabetic patients using portable insulin infusion pump therapy: a preliminary investigation.

Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.

Cohen N, Minshall ME, Sharon-Nash L, et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.